Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458–67.

Article  PubMed  Google Scholar 

Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67(2):147–57.

Article  CAS  PubMed  Google Scholar 

Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update. Allergy. 2022;77(7):1961–90.

Article  PubMed  Google Scholar 

Riedl MA, Bordone L, Revenko A, et al. Clinical progress in hepatic targeting for novel prophylactic therapies in hereditary angioedema. J Allergy Clin Immunol Pract. 2024;12(4):911–8.

Article  CAS  PubMed  Google Scholar 

Cohn DM, Viney NJ, Fijen LM, et al. Antisense inhibition of prekallikrein to control hereditary angioedema. N Engl J Med. 2020;383(13):1242–7.

Article  CAS  PubMed  Google Scholar 

Ferrone JD, Bhattacharjee G, Revenko AS, et al. IONIS-PKKRx a novel antisense inhibitor of prekallikrein and bradykinin production. Nucleic Acid Ther. 2019;29(2):82–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crooke ST, Baker BF, Xia S, et al. Integrated assessment of the clinical performance of GalNAc3-conjugated 2′-O-methoxyethyl chimeric antisense oligonucleotides: i. human volunteer experience. Nucleic Acid Ther. 2019;29(1):16–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ionis Pharmaceuticals. DAWNZERA™ (donidalorsen) approved in the US as first and only RNA-targeted prophylactic treatment for hereditary angioedema [media release]. 21 Aug 2025. https://ir.ionis.com/.

US Food and Drug Administration. DAWNZERA™ (donidalorsen) injection, for subcutaneous use: US prescribing information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf. Accessed 2 Oct 2025.

Otsuka Pharmaceutical. European Medicines Agency commences review of donidalorsen in hereditary angioedema [media release]. 6 Jan 2025. http://www.otsuka.com.

European Commission. Community register of orphan medicinal products. 2024. https://ec.europa.eu/health/documents/community-register/html/o2898.htm. Accessed 2 Oct 2025.

US Food and Drug Administration. Orphan Drug designations and approvals. 2023. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=961723. Accessed 2 Oct 2025.

Theratechnologies. Theratechnologies announces exclusive licensing agreement with Ionis to commercialize olezarsen and donidalorsen in Canada [media release]. 4 Dec 2024. http://www.theratech.com.

Ionis Pharmaceuticals. Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema [media release]. 18 Dec 2023. https://ir.ionis.com/.

Ionis Pharmaceuticals. Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema [media release]. 18 Jun 2024. http://www.ionis.com.

Riedl MA, Tachdjian R, Lumry WR, et al. Efficacy and safety of donidalorsen for hereditary angioedema. N Engl J Med. 2024;391(1):21–31.

Article  CAS  PubMed  Google Scholar 

Fijen LM, Riedl MA, Bordone L, et al. Inhibition of prekallikrein for hereditary angioedema. N Engl J Med. 2022;386(11):1026–33.

Article  CAS  PubMed  Google Scholar 

Singh P, Witjes H, Kleijn H, et al. Donidalorsen exposure-response analysis: hereditary angioedema attack rate versus plasma prekallikrein concentration relationship [abstract no. R073]. Ann Allergy Asthma Immunol. 2024;133(Suppl 6):S25.

Article  Google Scholar 

Khatri H, Estepa P, Cummings B. Participant reported ease-of-use with a prefilled, single-dose, disposable autoinjector for the treatment of hereditary angioedema [abstract no. 699]. J Allergy Clin Immunol. 2025;155(Suppl 2):AB228.

Article  Google Scholar 

Riedl MA, Yarlas A, Bordone L, et al. Patient-reported outcomes in the phase III OASIS-HAE study of donidalorsen for hereditary angioedema. Allergy. 2025;80(8):2361–8.

Article  CAS  PubMed  Google Scholar 

Riedl MA, Bernstein JA, Jacobs JS, et al. Donidalorsen treatment of hereditary angioedema in patients previously on long-term prophylaxis. J Allergy Clin Immunol Pract. 2025. https://doi.org/10.1016/j.jaip.2025.06.018.

Article  PubMed  Google Scholar 

Tachdjian R, Riedl M, Bordone L, et al. Donidalorsen for hereditary angioedema: results from the OASISplus open-label extension study [abstract no. R110 plus Poster]. Ann Allergy Asthma Immunol. 2024;133(Suppl 6):S38.

Article  Google Scholar 

Petersen RS, Bordone L, Riedl MA, et al. A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema. Allergy. 2023;79(3):724–34.

Article  PubMed  Google Scholar 

Manning M, Bordone L, Cohn D, et al. Long-term analysis of the phase 2 open-label extension of donidalorsen in patients with hereditary angioedema [abstract no. 654 plus Poster]. J Allergy Clin Immunol. 2025;155(Suppl 2):AB213.

Google Scholar 

Riedl M, Bernstein J, Tachdjian R, et al. Patient-reported injection-site pain and treatment satisfaction after switching from long-term prophylaxis to donidalorsen for the treatment of hereditary angioedema: results from The OASISplus study [abstract no. 599 plus Poster]. J Allergy Clin Immunol. 2025;155(Suppl 2):AB193.

Article  Google Scholar 

Tachdjian R, Riedl MA, Bordone L, et al. Long-term safety of donidalorsen for the treatment of hereditary angioedema: results from the phase 3 open-label extension OASISplus study [abstract no. 100146]. Allergy. 2024;79(S113):149–50.

Google Scholar